KIYATEC Expands Greenville, South Carolina, Operations
12/17/2021
Located at 2 N. Main Street, the downtown facility will allow the company to expand its existing clinical testing operations and drug development services which are co-located with the Cancer Institute at nearby Prisma Health’s Memorial Campus. The new offices are expected to be operational by January 2022 and the CLIA-certified laboratory by April 2022.
“Securing testing capacity to bring our testing to thousands, then tens of thousands of cancer patients is a business decision that positions us to win and increases our competitive advantage. As a Greenville-based life sciences company, KIYATEC benefits from all this area has to offer including its highly-educated labor force, excellent quality of life for our employees, competitive cost profile and business-friendly environment. We are proud to be a part of the growing business and scientific communities here in Greenville and appreciate the ongoing support from our community leaders in this exciting new phase of our company’s journey.” Said KIYATEC, Inc. CEO Matt Gevaert, Ph.D.
“We’re thrilled to see KIYATEC, Inc. thriving and expanding in South Carolina. The company’s decision to invest $5 million and create 91 new jobs in Greenville County is great news for our state, the Upstate region and our life sciences industry,” noted Secretary of Commerce Harry M. Lightsey III.
Founded in 2005, KIYATEC, Inc. is a commercial stage cancer diagnostics company born from technology developed at Clemson University, creating transformative solutions for cancer patients using functional precision oncology. KIYATEC, Inc. recently launched its first commercial assay 3D Predict™ Glioma for use in glioblastoma (commonly known as GBM) and other brain cancer patient care.
“As a leading functional precision oncology company, KIYATEC is solving medical problems and saving lives through cutting-edge science. Greenville County congratulates KIYATEC on their growth and expansion here in our community, and we wish them continued success,” Greenville County Council Chairman and Greenville Area Development Corporation Board Member Willis Meadows noted.
The company established its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory and began clinical studies in 2015, developing proprietary “ex vivo” 3D cell culture technology platforms to accurately model and predict patient-specific response to approved and investigational cancer drugs targeting a spectrum of solid tumors.
Project Announcements
Huber Engineered Woods Plans Shuqualak, Mississippi, Manufacturing Plant
06/09/2023
Gaffney Bakery Plans Gaffney, South Carolina, Frozen Bakery Products Plant
06/09/2023
Itron Establishes West Union, South Carolina, Center Of Excellence
06/09/2023
Devele Establishes Butte, Montana, Manufacturing Plant
06/09/2023
Manner Polymers Plans Mount Vernon, Illinois, Manufacturing Plant
06/09/2023
Purolite Establishes Landenberg, Pennsylvania, Global Biologics Division
06/08/2023
Most Read
-
EV and Semiconductor Projects Stand Out in States Receiving Area Development’s 18th Annual Shovel Awards
Q2 2023
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Is a Flurry of Fads Shaping Economic Development Policy?
Q2 2023
-
Front Line: Water Supply Increasingly Affecting Location Decisions
Q2 2023
-
Life Science Conversions in Real Estate
Q2 2023
-
Nearshoring — North America’s Next Factory
Q2 2023
-
First Person: Labor Crunch in the Construction Industry
Q2 2023